Melanotan 2: Tanning Peptide Benefits, Risks, and Dosing
A synthetic alpha-MSH analog that darkens skin without a tanning bed. How it works through MC1R activation, what the side effects actually look like, and why the melanoma question still isn't settled.
Target Receptor
Full Tan
Receptors Activated
Approval
Melanotan 2 - also known as the "Barbie peptide" or "Barbie drug" on social media - is one of the most popular and most controversial peptides in the cosmetic space. It darkens your skin without a tanning bed.
It can boost libido. It may suppress appetite. And it carries real risks that anyone considering it needs to understand before moving forward. The "Barbie" nickname caught on through TikTok and wellness communities, but the compound itself has been around since the 1990s, originally developed at the University of Arizona.
MT-2 is not FDA-approved and carries unresolved safety concerns, including a possible link to melanoma. This guide is educational only. Consult a qualified healthcare provider before considering any peptide protocol.
Melanotan 2 at a Glance
Melanotan 2 (alpha-MSH Analog)
Type: Synthetic analog of alpha-MSH | Primary Target: MC1R (melanocortin 1 receptor) | Secondary Targets: MC3R, MC4R, MC5R | Primary Effect: Skin darkening (eumelanin production) | Secondary Effects: Sexual arousal, appetite suppression | Route: Subcutaneous injection | FDA Status: Not approved | Related: PT-141 (bremelanotide), derived from MT-2 research
MT-2 was originally developed at the University of Arizona in the 1990s as a potential preventive treatment for skin cancer. The idea was straightforward: if you could darken people's skin without UV exposure, you could protect them from UV damage.
The compound never made it through formal drug development. But it found a second life in the underground peptide market for cosmetic tanning and its sexual side effects.
MT-2 is closely related to bremelanotide (PT-141), which was derived from MT-2 research and eventually received FDA approval for treating hypoactive sexual desire disorder in women. For a deeper compound profile, visit PeptideArc.
How Melanotan 2 Works
MT-2 is a non-selective agonist of melanocortin receptors, binding to MC1R through MC5R. This non-selectivity is why it produces such a wide range of effects, from skin darkening to sexual arousal to appetite changes.
Receptor Activity and Effects
| Receptor | Location | Effect |
|---|---|---|
| MC1R | Melanocytes (skin) | Skin darkening, eumelanin production |
| MC3R | Brain, gut | Energy balance, fat metabolism |
| MC4R | Hypothalamus | Sexual arousal, appetite suppression |
| MC5R | Various tissues | Sebaceous gland regulation |
The MC1R Tanning Cascade
MT-2 produces eumelanin, the dark brown/black pigment that actually provides UV protection. This is different from pheomelanin (the reddish pigment in fair-skinned, red-haired individuals), which doesn't protect against UV and may generate free radicals.
MT-2 can be particularly effective for fair-skinned individuals whose melanocytes can produce eumelanin but typically don't. Some UV exposure is still needed to optimize the tan, but far less than without the peptide.
MC4R: Sexual and Appetite Effects
Sexual arousal from MC4R activation in the hypothalamus is often the most noticeable effect, sometimes occurring before any visible skin darkening. This effect was so pronounced that researchers developed PT-141 (bremelanotide) specifically to target it, receiving FDA approval in 2019 as Vyleesi (Clayton et al., 2016).
Appetite suppression through MC4R is also real but inconsistent. It's usually not dramatic enough to be the primary reason for using the peptide (Adan et al., 2006).
What to Expect: Timeline
Results with MT-2 don't happen overnight. Here's a realistic timeline based on common user experiences.
| Phase | Timeline | What Happens |
|---|---|---|
| First injection | Hours | Sexual arousal effects, possible nausea and flushing |
| Loading (Week 1–2) | 5–10 days | Skin darkening begins; fair skin may take longer |
| Loading (Week 2–3) | 2–3 weeks | Color develops, may appear slightly uneven initially |
| Full tan | 3–4 weeks | Desired shade reached, even distribution |
| Maintenance | Ongoing | Less frequent dosing maintains color |
| After stopping | 1–3 months | Tan fades gradually as skin cells turn over |
MT-2 will darken existing moles and freckles. New moles may also appear. This is both a cosmetic concern and a safety consideration. If you have moles, monitor them closely during and after use.
Dosing Protocols
MT-2 is administered via subcutaneous injection, typically into the abdominal fat. For technique, see our subcutaneous injection guide.
Need help with dosing math? Use our free Peptide Reconstitution Calculator.
Reconstitution
MT-2 typically comes as lyophilized powder in 10 mg vials. Adding 1 mL of bacteriostatic water gives a concentration of 10 mg/mL for easy dose measurement.
Loading Phase
| Parameter | Recommendation |
|---|---|
| Starting dose | 0.1–0.25 mg (assess tolerance) |
| Working dose | 0.25–0.5 mg |
| Frequency | Once daily, preferably evening |
| Duration | 2–4 weeks or until desired tan |
| UV exposure | Brief sessions (10–20 min), 2–3x/week |
Maintenance Phase
| Parameter | Recommendation |
|---|---|
| Dose | 0.25–0.5 mg |
| Frequency | Once or twice per week |
| UV exposure | Minimal, once per week or as needed |
Dosing Tips
Start Low
Nausea is dose-dependent. Beginning at 0.1 mg lets your body adjust gradually.
Evening Dosing
Inject before bed. You'll sleep through the worst of the nausea and flushing.
Antihistamines Help
Diphenhydramine 30 minutes before injection can reduce nausea and flushing significantly.
Don't Chase Results
Higher doses increase side effects without proportionally improving tanning speed.
Storage
Reconstituted MT-2 should be refrigerated and used within 4–6 weeks. Unreconstituted powder lasts longer when refrigerated or frozen. For detailed storage tips, see our peptide storage guide.
Side Effects
MT-2 has a well-documented side effect profile. Most are dose-dependent and improve with continued use. For a broader overview, see our peptide side effects guide.
Common Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Nausea | 50–70% | Worst early on, improves with tolerance |
| Facial flushing | Common | 15–30 min after injection, lasts 30–60 min |
| Fatigue/drowsiness | Common | Another reason for evening dosing |
| Appetite suppression | Mild | Can be welcome for some |
| Injection site reactions | Common | Minor redness, itching |
Less Common Side Effects
| Side Effect | Notes |
|---|---|
| Spontaneous erections | Pronounced MC4R effect in men |
| Mole/freckle darkening | Essentially universal with sufficient use |
| New mole formation | Reported by some users |
| Stomach cramping | Accompanies nausea, resolves similarly |
| Dizziness | Occasional, mild, transient |
Serious Side Effects
Melanoma risk: Unresolved (see dedicated section below) | Rhabdomyolysis: Extremely rare case reports, unclear causality | Priapism: Prolonged erections at higher doses, may require medical attention
The Melanoma Question
The melanoma risk question is unresolved. If you have a personal or family history of melanoma, do not use MT-2. Period.
Melanoma develops from melanocytes, the same cells MT-2 stimulates. Chronic stimulation could theoretically promote malignant transformation. This is the single biggest safety concern with the compound.
Evidence Summary
| Evidence Type | Finding | Weight |
|---|---|---|
| Case reports | Melanoma diagnoses in MT-2 users reported (Hjuler et al., 2015) | Can't establish causation |
| Animal data | MT-2 did not promote melanoma growth in one mouse model (Langan et al., 2009) | Somewhat reassuring |
| Mechanistic concern | Melanocyte activation could accelerate pre-existing atypical cells | Theoretically plausible |
| Population data | No large-scale epidemiological studies exist | Major data gap |
Practical Guidance
High Risk
Personal or family history of melanoma? Do not use MT-2. The risk calculus is clearly negative.
Elevated Risk
Many atypical moles? The risk-benefit ratio shifts unfavorably. Consider alternatives.
If Using MT-2
Monitor skin carefully, get regular dermatologist checks, and minimize UV exposure.
Mole darkening also makes self-monitoring harder, which is itself a safety concern. If you can't tell whether a mole is changing because of MT-2 or something else, that's a problem.
Other Safety Considerations
Contamination Risk
MT-2 is not pharmaceutical grade. Studies analyzing online peptides have found purity issues, incorrect dosing, and contamination (Cohen et al., 2023). Buy from suppliers providing third-party COAs showing HPLC purity and endotoxin testing.
Long-Term Effects
MT-2 has been used recreationally for 15–20 years. No systematic long-term data exists. We genuinely don't know what 10+ years of intermittent melanocyte stimulation does to the body.
MT-2 makes you more responsive to UV. The eumelanin it produces is protective, but UV still causes DNA damage regardless of melanin levels. Use reasonable sun exposure practices even with the added pigmentation.
Melanotan 1 vs. Melanotan 2
These two peptides are often confused. They share a common origin but differ significantly in their receptor selectivity and side effect profiles.
| Feature | Melanotan 1 (Afamelanotide) | Melanotan 2 |
|---|---|---|
| Selectivity | More selective MC1R agonist | Non-selective (MC1R–MC5R) |
| Tanning effect | Yes | Yes |
| Sexual side effects | Minimal | Significant |
| Nausea | Less | More |
| Approved use | EU-approved (Scenesse) for EPP | Not approved anywhere |
| Availability | Harder to obtain, more expensive | Widely available |
Legal Status
MT-2 occupies a gray area in most countries. For a full breakdown, see our peptide regulations guide.
| Country | Status |
|---|---|
| United States | Not FDA-approved, not scheduled; sold as "research chemical" |
| United Kingdom | Illegal to sell, legal to possess for personal use |
| Australia | Schedule 4 (prescription-only); importing without prescription is illegal |
| European Union | Not approved; regulations vary by country |
| Canada | Not approved; available from research suppliers |
The regulatory situation could change. Several countries have discussed tightening regulations on cosmetic peptides.
Who Might Consider MT-2
Fair-Skinned Individuals
People with Fitzpatrick skin types I–II who want a tan but burn easily with UV exposure. MT-2 can produce eumelanin in skin that normally makes very little.
Minimal UV Goals
Those who want tanned skin while minimizing total UV exposure. MT-2 reduces the amount of sun time needed to maintain color.
Anyone with a personal or family history of melanoma, a large number of atypical moles, or an inability to commit to regular dermatological monitoring. Pregnant or breastfeeding individuals should also avoid MT-2 entirely.
Frequently Asked Questions
How long does it take for MT-2 to work?
Do you still need sun exposure with MT-2?
How long does the tan last after stopping?
Can women use MT-2?
Is MT-2 the same as PT-141?
Will MT-2 protect me from sunburn?
Can MT-2 cause permanent skin changes?
What about nasal sprays?
The Bottom Line
MT-2 works for tanning. It produces real eumelanin, creates a natural-looking tan, and does so with minimal UV exposure. But it carries unresolved safety questions, particularly around melanoma risk, that demand careful consideration.
The sexual side effects are a bonus for many users. The appetite suppression is a mild perk. But these secondary effects shouldn't overshadow the primary concern: this is a compound that stimulates the same cells melanoma arises from.
Add in the lack of regulation, potential purity issues, and unknown long-term safety profile, and you have a compound that demands informed decision-making.
If you choose to use MT-2, start with low doses, monitor your skin carefully, get regular dermatologist checks, and stay honest with yourself about the risk-benefit tradeoff.
This article is for educational and informational purposes only. It is not medical advice, and it is not a recommendation to use Melanotan 2. MT-2 is not FDA-approved and carries unresolved safety concerns. Always consult a qualified healthcare provider before starting any peptide protocol. Never self-treat, self-diagnose, or ignore professional medical advice based on information found online.
References
Clayton AH et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325–337. PubMed
Adan RA et al. The MC4 receptor and control of appetite. Br J Pharmacol. 2006;149(7):815–827. PubMed
Hjuler KF et al. Melanoma associated with the use of melanotan-II. Dermatology. 2015;230(3):263–267. PubMed
Langan EA et al. The effects of alpha-melanocyte stimulating hormone on human melanoma in vitro and in a xenotransplant mouse model. Melanoma Res. 2009;19(1):14–21. PubMed
Cohen PA et al. Quantity of active ingredients in illegally marketed peptide products. JAMA Netw Open. 2023;6(1):e2251697. PubMed
Related reading:
PT-141 (Bremelanotide) Guide · Peptide Side Effects: What to Know · How to Inject Peptides · Peptide Legal Status 2026
For compound profiles and sourcing info, visit PeptideArc.